摘要
系统评价参麦注射液辅助治疗慢性心力衰竭(chronic heart failure,CHF)的有效性和安全性。检索Pubmed,CBM,CNKI,万方和VIP,全面收集参麦注射液治疗CHF所有类型的临床研究。其中有效性分析纳入随机对照试验(RCT),并对其进行质量评价,采用Rev-Man 5.2软件进行统计分析。现有研究表明,在常规治疗基础上加用参麦注射液可改善CHF患者的NYHA心功能分级好转率,左室射血分数,心排出量、每搏出量,脑钠肽,6 min步行试验值,而在改善HR方面未显示明显效果。尚未发现参麦注射液治疗CHF所导致的严重ADR/AE。
The paper is to evaluate the efficacy and safety of Shenmai injection for chronic heart failure,retrieving the Pubmed,CBM,CNKI,Wanfang database and VIP database to comprehensively collect all types research report of Shenmai injection for chronic heart failure（CHF）.Particularly wishing to point out,randomized controlled trials are include for the evaluation of effectiveness,which are statistically analyzed and evaluated by Rev-Man 5.2.The current studies show that the improvement rate of NYHA classification of cardiac function of CHF patients and their related indexes figure such as LVEF,SV,CO,BNP,6 rain walking test value are all improved by the combination of Shenmai injection and foundation treatment.However,HR is almost no improvement.Meanwhile,serious ADR/AE of Shenmai injection for CHF isn＇t appear.
出处
《中国中药杂志》
CAS
CSCD
北大核心
2014年第18期3650-3661,共12页
China Journal of Chinese Materia Medica
基金
国家"重大新药创制"科技重大专项(2009XZ09520030)
